PMID- 31464209
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231013
IS  - 0970-2113 (Print)
IS  - 0974-598X (Electronic)
IS  - 0970-2113 (Linking)
VI  - 36
IP  - 5
DP  - 2019 Sep-Oct
TI  - Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus 
      strategy: A 2 years' experience.
PG  - 384-392
LID - 10.4103/lungindia.lungindia_475_18 [doi]
AB  - BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is a global health problem 
      with notoriously difficult and challenging treatment. This study determined 
      treatment outcome in patients of MDR-TB with modified DOTS-Plus strategy. 
      METHODS: Ninety-eight consecutive MDR-TB patients treated with standardized 
      regimen according to modified DOTS-Plus strategy aligned to the existing national 
      DOTS-Plus guidelines with relevant modifications proposed by Chennai consensus 
      were analyzed prospectively. Treatment included monthly follow-up with clinical, 
      radiological, and bacteriological assessment (sputum smear advised monthly till 
      conversion then quarterly; culture for Mycobacterium tuberculosis at 0, 4, 6, 12, 
      18, and 24 months), ensuring adherence, intense health education, and monitoring 
      of adverse events (AEs). Patients' outcome was considered as cure when at least 
      two of the last three cultures (all three or last two) were negative and as 
      failure when the same were positive. RESULTS: Favorable and unfavorable outcomes 
      in this cohort were reported to be 71/98 (72.4%) and 27/98 (27.6%) (failure - 10 
      [10.2%], default - 7 [7.1%], and expiry - 10 [10.2%]), respectively. Sputum smear 
      and culture conversion rate were 75/81 (92.5%) and 71/81 (87.7%), respectively. 
      Major AEs were experienced in only 17.4% of patients. CONCLUSIONS: MDR-TB can be 
      cured successfully with modified DOTS-Plus strategy and requires much effort from 
      both the patients and health-care workers. It can be an alternative model for 
      treating MDR-TB patients in private sector.
FAU - Singh, Abhijeet
AU  - Singh A
AD  - Department of Pulmonary Medicine, King George Medical College, Lucknow, Uttar 
      Pradesh, India.
FAU - Prasad, Rajendra
AU  - Prasad R
AD  - Department of Pulmonary Medicine, King George Medical College, Lucknow, Uttar 
      Pradesh, India.
FAU - Kushwaha, Ram Awadh Singh
AU  - Kushwaha RAS
AD  - Department of Pulmonary Medicine, King George Medical College, Lucknow, Uttar 
      Pradesh, India.
FAU - Srivastava, Rahul
AU  - Srivastava R
AD  - Department of Pulmonary Medicine, King George Medical College, Lucknow, Uttar 
      Pradesh, India.
FAU - Giridhar, Belur Hosmane
AU  - Giridhar BH
AD  - Department of Pulmonary Medicine, King George Medical College, Lucknow, Uttar 
      Pradesh, India.
FAU - Balasubramanian, Viswesvaran
AU  - Balasubramanian V
AD  - Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University 
      of Delhi, Delhi, India.
FAU - Jain, Amita
AU  - Jain A
AD  - Department of Microbiology, King George Medical College, Lucknow, Uttar Pradesh, 
      India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC6710973
OTO - NOTNLM
OT  - Drug resistant
OT  - individualized
OT  - programmatic management of multidrug-resistant tuberculosis
OT  - regimen
OT  - standardized
OT  - tuberculosis
COIS- None
EDAT- 2019/08/30 06:00
MHDA- 2019/08/30 06:01
PMCR- 2019/09/01
CRDT- 2019/08/30 06:00
PHST- 2019/08/30 06:00 [entrez]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2019/08/30 06:01 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - LungIndia_2019_36_5_384_265180 [pii]
AID - LI-36-384 [pii]
AID - 10.4103/lungindia.lungindia_475_18 [doi]
PST - ppublish
SO  - Lung India. 2019 Sep-Oct;36(5):384-392. doi: 10.4103/lungindia.lungindia_475_18.